Jeffrey Miller, MD, will begin his role as Director of the Masonic Cancer Center (MCC) on Dec. 15. He will continue the work he has led as MCC’s Interim Director over the past year, including preparing for the next Cancer Center Support Grant renewal and continuing to advance the Masonic Cancer Center’s excellence in research, innovative and multidisciplinary collaboration and partnership with communities.
Miller is a longstanding MCC and University of Minnesota faculty member, having joined the Medical School's Department of Medicine in 1991. Over the years he has held many leadership roles in MCC, including serving as its Deputy Director and Co-Leader of the Immunology Program. He also holds the Roger L. and Lynn C. Headrick Chair in Cancer Therapeutics at the Medical School.
He is a dedicated researcher and active physician who focuses on blood cancers, blood and marrow transplant, and cancer immunotherapy, with grants now going beyond leukemia to treat solid tumors. His research focuses on how stem cells develop into functioning natural killer (NK) cells and investigates how to manipulate NK cells with chimeric antigen receptors (CARs) or immune engagers to make NK cells antigen specific.
"Dr. Miller's longstanding commitment to MCC and the University has been exemplary," says Jakub Tolar, MD, PhD, Vice President for Clinical Affairs. "I am excited about the future under his leadership and the promising opportunity to strategically advance the Masonic Cancer Center’s excellence in research, innovation and multidisciplinary collaboration."
Other News
